Literature DB >> 8750253

Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.

G R Thompson1, J Hollyer, D D Waters.   

Abstract

We have analysed 11 trials which used quantitative angiography to assess the effects of lipid-lowering therapy on coronary atherosclerosis. Linear regression, weighted for the number of patients studied, showed that the change in per cent diameter stenosis was significantly correlated with per cent reduction in LDL-cholesterol (r = 0.74, p < 0.0005), but not with the LDL-cholesterol concentration during the trials. These findings have important implications for the secondary prevention of coronary heart disease.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8750253     DOI： 10.1097/00041433-199512000-00010

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN： 0957-9672            Impact factor:   4.776


  10 in total

1.  Clinical implications of statin event trials.

Authors:  Anne Carol Goldberg
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

Review 2.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

3.  The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.

Authors:  S Efrati; M Averbukh; V Dishy; M Faygenzo; L Friedensohn; A Golik
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 4.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Authors:  Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2009-10       Impact factor: 5.223

5.  Cholesterol: how low is low enough?

Authors:  A Rosengren
Journal:  BMJ       Date:  1998-08-15

Review 6.  [Goals and practical implementation of lipid therapy in coronary heart disease].

Authors:  F U Beil; E Windler
Journal:  Herz       Date:  1997-06       Impact factor: 1.443

Review 7.  The pharmacodynamic and clinical trial evidence for statin dose.

Authors:  Simon B Dimmitt; Hans G Stampfer; John B Warren
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

8.  Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia : The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study.

Authors:  T J Smilde; M D Trip; H Wollersheim; S van Wissen; J J Kastelein; A F Stalenhoef
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

Review 9.  PROVE-IT proved it: lower is better--pro.

Authors:  Lawrence A Leiter
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 10.  Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention.

Authors:  Ismail Dogu Kilic; Enrico Fabris; Elvin Kedhi; Liviu-Nicolae Ghilencea; Gianluca Caiazzo; Sara Abou Sherif; Carlo Di Mario
Journal:  Curr Atheroscler Rep       Date:  2020-10-06       Impact factor: 5.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.